GELESIS HOLDINGS INC (GLS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:GLS - US36850R2040 - Common Stock
0.1586 USD
+0 (+0.38%)
0.1555 USD
0 (-1.95%)
We assign a fundamental rating of 1 out of 10 to GLS. GLS was compared to 528 industry peers in the Biotechnology industry. Both the profitability and financial health of GLS have multiple concerns. GLS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- GLS had negative earnings in the past year.
- GLS had a negative operating cash flow in the past year.
1.2 Ratios
- The profitability ratios for GLS are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- GLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- GLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, GLS has more shares outstanding
- Compared to 1 year ago, GLS has a worse debt to assets ratio.
2.2 Solvency
- GLS has an Altman-Z score of -8.60. This is a bad value and indicates that GLS is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of GLS (-8.60) is worse than 77.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.6 |
ROIC/WACCN/A
WACC5.71%
2.3 Liquidity
- A Current Ratio of 0.30 indicates that GLS may have some problems paying its short term obligations.
- GLS has a Current ratio of 0.30. This is amonst the worse of the industry: GLS underperforms 94.45% of its industry peers.
- GLS has a Quick Ratio of 0.30. This is a bad value and indicates that GLS is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.21, GLS is not doing good in the industry: 94.93% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.3 | ||
| Quick Ratio | 0.21 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 66.00% over the past year.
- Looking at the last year, GLS shows a very strong growth in Revenue. The Revenue has grown by 80.37%.
EPS 1Y (TTM)66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.08%
Revenue 1Y (TTM)80.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-76.5%
3.2 Future
- Based on estimates for the next years, GLS will show a very strong growth in Earnings Per Share. The EPS will grow by 36.67% on average per year.
- The Revenue is expected to grow by 68.56% on average over the next years. This is a very strong growth
EPS Next Y78.59%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year80.41%
Revenue Next 2Y68.56%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for GLS. In the last year negative earnings were reported.
- Also next year GLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as GLS's earnings are expected to grow with 36.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.67%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for GLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.1586
+0 (+0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-23 2023-03-23/bmo
Earnings (Next)05-10 2023-05-10/bmo
Inst Owners16.44%
Inst Owner Change0%
Ins Owners24.71%
Ins Owner Change0%
Market Cap11.63M
Revenue(TTM)25.77M
Net Income(TTM)-95.06M
Analysts45
Price Target0.46 (190.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)41.93%
Min EPS beat(2)41.93%
Max EPS beat(2)41.93%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.45 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.31
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.06
OCFYN/A
SpS0.35
BVpS-0.34
TBVpS-0.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 166.18% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.3 | ||
| Quick Ratio | 0.21 | ||
| Altman-Z | -8.6 |
F-Score2
WACC5.71%
ROIC/WACCN/A
Cap/Depr(3y)616.89%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.08%
EPS Next Y78.59%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)80.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-76.5%
Revenue Next Year80.41%
Revenue Next 2Y68.56%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.58%
OCF growth 3YN/A
OCF growth 5YN/A
GELESIS HOLDINGS INC / GLS FAQ
What is the ChartMill fundamental rating of GELESIS HOLDINGS INC (GLS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to GLS.
Can you provide the valuation status for GELESIS HOLDINGS INC?
ChartMill assigns a valuation rating of 0 / 10 to GELESIS HOLDINGS INC (GLS). This can be considered as Overvalued.
Can you provide the profitability details for GELESIS HOLDINGS INC?
GELESIS HOLDINGS INC (GLS) has a profitability rating of 0 / 10.
Can you provide the financial health for GLS stock?
The financial health rating of GELESIS HOLDINGS INC (GLS) is 0 / 10.